Which strategies reduce breast cancer mortality most?

Collaborative modeling of optimal screening, treatment, and obesity prevention

Jeanne Mandelblatt, Nicolien Van Ravesteyn, Clyde B. Schechter, Yaojen Chang, An Tsun Huang, Aimee M. Near, Harry De Koning, Ahmedin Jemal

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND US breast cancer mortality is declining, but thousands of women still die each year. METHODS Two established simulation models examine 6 strategies that include increased screening and/or treatment or elimination of obesity versus continuation of current patterns. The models use common national data on incidence and obesity prevalence, competing causes of death, mammography characteristics, treatment effects, and survival/cure. Parameters are modified based on obesity (defined as BMI ≥ 30 kg/m2). Outcomes are presented for the year 2025 among women aged 25+ and include numbers of cases, deaths, mammograms and false-positives; age-adjusted incidence and mortality; breast cancer mortality reduction and deaths averted; and probability of dying of breast cancer. RESULTS If current patterns continue, the models project that there would be about 50,100-57,400 (range across models) annual breast cancer deaths in 2025. If 90% of women were screened annually from ages 40 to 54 and biennially from ages 55 to 99 (or death), then 5100-6100 fewer deaths would occur versus current patterns, but incidence, mammograms, and false-positives would increase. If all women received the indicated systemic treatment (with no screening change), then 11,400-14,500 more deaths would be averted versus current patterns, but increased toxicity could occur. If 100% received screening plus indicated therapy, there would be 18,100-20,400 fewer deaths. Eliminating obesity yields 3300-5700 fewer breast cancer deaths versus continuation of current obesity levels. CONCLUSIONS Maximal reductions in breast cancer deaths could be achieved through optimizing treatment use, followed by increasing screening use and obesity prevention.

Original languageEnglish (US)
Pages (from-to)2541-2548
Number of pages8
JournalCancer
Volume119
Issue number14
DOIs
StatePublished - Jul 15 2013

Fingerprint

Obesity
Breast Neoplasms
Mortality
Therapeutics
Incidence
Mammography
Cause of Death
Survival

Keywords

  • breast cancer
  • mammography
  • modeling
  • obesity
  • simulation
  • treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention. / Mandelblatt, Jeanne; Van Ravesteyn, Nicolien; Schechter, Clyde B.; Chang, Yaojen; Huang, An Tsun; Near, Aimee M.; De Koning, Harry; Jemal, Ahmedin.

In: Cancer, Vol. 119, No. 14, 15.07.2013, p. 2541-2548.

Research output: Contribution to journalArticle

Mandelblatt, J, Van Ravesteyn, N, Schechter, CB, Chang, Y, Huang, AT, Near, AM, De Koning, H & Jemal, A 2013, 'Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention', Cancer, vol. 119, no. 14, pp. 2541-2548. https://doi.org/10.1002/cncr.28087
Mandelblatt, Jeanne ; Van Ravesteyn, Nicolien ; Schechter, Clyde B. ; Chang, Yaojen ; Huang, An Tsun ; Near, Aimee M. ; De Koning, Harry ; Jemal, Ahmedin. / Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention. In: Cancer. 2013 ; Vol. 119, No. 14. pp. 2541-2548.
@article{ff592e63e9c3444a946cf008313f5948,
title = "Which strategies reduce breast cancer mortality most?: Collaborative modeling of optimal screening, treatment, and obesity prevention",
abstract = "BACKGROUND US breast cancer mortality is declining, but thousands of women still die each year. METHODS Two established simulation models examine 6 strategies that include increased screening and/or treatment or elimination of obesity versus continuation of current patterns. The models use common national data on incidence and obesity prevalence, competing causes of death, mammography characteristics, treatment effects, and survival/cure. Parameters are modified based on obesity (defined as BMI ≥ 30 kg/m2). Outcomes are presented for the year 2025 among women aged 25+ and include numbers of cases, deaths, mammograms and false-positives; age-adjusted incidence and mortality; breast cancer mortality reduction and deaths averted; and probability of dying of breast cancer. RESULTS If current patterns continue, the models project that there would be about 50,100-57,400 (range across models) annual breast cancer deaths in 2025. If 90{\%} of women were screened annually from ages 40 to 54 and biennially from ages 55 to 99 (or death), then 5100-6100 fewer deaths would occur versus current patterns, but incidence, mammograms, and false-positives would increase. If all women received the indicated systemic treatment (with no screening change), then 11,400-14,500 more deaths would be averted versus current patterns, but increased toxicity could occur. If 100{\%} received screening plus indicated therapy, there would be 18,100-20,400 fewer deaths. Eliminating obesity yields 3300-5700 fewer breast cancer deaths versus continuation of current obesity levels. CONCLUSIONS Maximal reductions in breast cancer deaths could be achieved through optimizing treatment use, followed by increasing screening use and obesity prevention.",
keywords = "breast cancer, mammography, modeling, obesity, simulation, treatment",
author = "Jeanne Mandelblatt and {Van Ravesteyn}, Nicolien and Schechter, {Clyde B.} and Yaojen Chang and Huang, {An Tsun} and Near, {Aimee M.} and {De Koning}, Harry and Ahmedin Jemal",
year = "2013",
month = "7",
day = "15",
doi = "10.1002/cncr.28087",
language = "English (US)",
volume = "119",
pages = "2541--2548",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "14",

}

TY - JOUR

T1 - Which strategies reduce breast cancer mortality most?

T2 - Collaborative modeling of optimal screening, treatment, and obesity prevention

AU - Mandelblatt, Jeanne

AU - Van Ravesteyn, Nicolien

AU - Schechter, Clyde B.

AU - Chang, Yaojen

AU - Huang, An Tsun

AU - Near, Aimee M.

AU - De Koning, Harry

AU - Jemal, Ahmedin

PY - 2013/7/15

Y1 - 2013/7/15

N2 - BACKGROUND US breast cancer mortality is declining, but thousands of women still die each year. METHODS Two established simulation models examine 6 strategies that include increased screening and/or treatment or elimination of obesity versus continuation of current patterns. The models use common national data on incidence and obesity prevalence, competing causes of death, mammography characteristics, treatment effects, and survival/cure. Parameters are modified based on obesity (defined as BMI ≥ 30 kg/m2). Outcomes are presented for the year 2025 among women aged 25+ and include numbers of cases, deaths, mammograms and false-positives; age-adjusted incidence and mortality; breast cancer mortality reduction and deaths averted; and probability of dying of breast cancer. RESULTS If current patterns continue, the models project that there would be about 50,100-57,400 (range across models) annual breast cancer deaths in 2025. If 90% of women were screened annually from ages 40 to 54 and biennially from ages 55 to 99 (or death), then 5100-6100 fewer deaths would occur versus current patterns, but incidence, mammograms, and false-positives would increase. If all women received the indicated systemic treatment (with no screening change), then 11,400-14,500 more deaths would be averted versus current patterns, but increased toxicity could occur. If 100% received screening plus indicated therapy, there would be 18,100-20,400 fewer deaths. Eliminating obesity yields 3300-5700 fewer breast cancer deaths versus continuation of current obesity levels. CONCLUSIONS Maximal reductions in breast cancer deaths could be achieved through optimizing treatment use, followed by increasing screening use and obesity prevention.

AB - BACKGROUND US breast cancer mortality is declining, but thousands of women still die each year. METHODS Two established simulation models examine 6 strategies that include increased screening and/or treatment or elimination of obesity versus continuation of current patterns. The models use common national data on incidence and obesity prevalence, competing causes of death, mammography characteristics, treatment effects, and survival/cure. Parameters are modified based on obesity (defined as BMI ≥ 30 kg/m2). Outcomes are presented for the year 2025 among women aged 25+ and include numbers of cases, deaths, mammograms and false-positives; age-adjusted incidence and mortality; breast cancer mortality reduction and deaths averted; and probability of dying of breast cancer. RESULTS If current patterns continue, the models project that there would be about 50,100-57,400 (range across models) annual breast cancer deaths in 2025. If 90% of women were screened annually from ages 40 to 54 and biennially from ages 55 to 99 (or death), then 5100-6100 fewer deaths would occur versus current patterns, but incidence, mammograms, and false-positives would increase. If all women received the indicated systemic treatment (with no screening change), then 11,400-14,500 more deaths would be averted versus current patterns, but increased toxicity could occur. If 100% received screening plus indicated therapy, there would be 18,100-20,400 fewer deaths. Eliminating obesity yields 3300-5700 fewer breast cancer deaths versus continuation of current obesity levels. CONCLUSIONS Maximal reductions in breast cancer deaths could be achieved through optimizing treatment use, followed by increasing screening use and obesity prevention.

KW - breast cancer

KW - mammography

KW - modeling

KW - obesity

KW - simulation

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84879613833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879613833&partnerID=8YFLogxK

U2 - 10.1002/cncr.28087

DO - 10.1002/cncr.28087

M3 - Article

VL - 119

SP - 2541

EP - 2548

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 14

ER -